---
schema_version: "secwatch.filing_event.v1"
accession: "0001558370-25-009663"
form_type: "8-K"
ticker: "PTCT"
cik: "0001070081"
company_name: "PTC THERAPEUTICS, INC."
filed_at: "2025-07-28T23:59:59+00:00"
generated_at: "2026-05-18T00:06:05.972143+00:00"
event_type: "regulatory"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# PTC Therapeutics receives FDA approval for Sephience (sepiapterin) to treat PKU in patients 1 month and older

## Summary
- FDA approved Sephience for hyperphenylalaninemia in adult/pediatric patients ≥1 month with sepiapterin-responsive PKU.
- Approval based on Phase 3 APHENITY trial and long-term extension data showing significant efficacy and safety.
- Broad labeling includes all disease subtypes; PTC CEO states Sephience could become standard of care.
- SEPHIENCE recently received EU marketing authorization; reviews ongoing in Japan, Brazil and other countries.
- PTC to host conference call July 28 at 5pm ET to discuss approval.

## SEC filing metadata
- accession: 0001558370-25-009663
- form_type: 8-K
- ticker: PTCT
- cik: 0001070081
- company_name: PTC THERAPEUTICS, INC.
- filed_at: 2025-07-28T23:59:59+00:00
- event_type: regulatory
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1070081/000155837025009663/0001558370-25-009663-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1070081/000155837025009663/tmb-20250728x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001558370-25-009663
- JSON: https://secwatch.observer/filing/0001558370-25-009663.json
- Plain text: https://secwatch.observer/filing/0001558370-25-009663.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.